Clinical trial · Interventional
Psycho-Educational Cognition Intervention in Patients With Blood and Lymph Cancer
A Study of the Feasibility and Acceptability of a Psycho-Educational Cognition Intervention in Adolescents and Young Adults (AYAs) With Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Feasibility
Summary
Brief summary (as posted)
This pilot trial studies how well a psycho-educational program called Emerging from the Haze works in helping patients with blood and lymph cancer. Sometimes, patients who have undergone treatment for cancer experience thinking or memory problems that make work, school, or everyday life activities, such as grocery shopping, difficult. The Emerging from the Haze program may provide resources to help deal with these types of challenges in patients with blood and lymph cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematopoietic and Lymphoid Cell Neoplasm | Hematopoietic and Lymphoid Cell Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Educational Intervention | Other | — | UNRESOLVED |
| Quality-of-Life Assessment | Other | — | UNRESOLVED |
| Survey Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Supportive Care (psycho-educational sessions)
- description
- Patients participate in a psycho-educational program weekly over 2 hours for 6 weeks.
- interventionNames
- Other: Educational Intervention
- Other: Quality-of-Life Assessment
- Other: Survey Administration
Primary outcomes (2)
- measure
- Enrollment of eligible participants (accrual)
- timeFrame
- Up to 30 days post the end of the six-week program
- description
- Feasibility will be assessed through enrollment of \>= 60% of eligible participants (accrual) and completion of at least 5 out of 6 sessions for \>= 80% of participants (adherence/engagement).
- measure
- Completion of sessions (adherence/engagement)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 39 Years
Show eligibility criteria text
Inclusion Criteria: * A diagnosis of a hematological malignancy. * Having received chemotherapy with or without radiation therapy. * Physician approval. * Functional Assessment of Cancer Therapy-Cognition (FACT-COG) score \< 59 on the perceived cognitive impairments (PCI) subscale. * Eligible after 2 months (60 +/- 5 days) of completing all their active cancer treatment with the exception of patients that are post-transplant. * Subjective complaint of cognitive concerns at time of enrollment. * Must be able to understand and communicate proficiently in English. * Ability to understand and the willingness to sign a written informed consent. * Agree to complete study surveys. Exclusion Criteria: * Patients who have significant personality disorders or unstable psychiatric disorders as assessed by the interviewing clinician. * Patients with known brain metastases, history of brain metastases or radiation to the brain. * Patients with a history of stroke or other pre-existing neurological condition that may contribute to cognitive dysfunction. * Non-English speaking patients.
References
Publications (0)
Data not yet available